国产伊马替尼与原研伊马替尼治疗初诊慢性髓性白血病慢性期的临床疗效及用药安全性对比分析

张江召; 赵哲; 黎纬明; 黄知平; 王红祥; 郭静明; 张新华; 张友山; 王丹; 鲍颖; 陈世明; 向航; 孟力

doi:10.13201/j.issn.1004-2806.2017.07.010

国产伊马替尼与原研伊马替尼治疗初诊慢性髓性白血病慢性期的临床疗效及用药安全性对比分析

- 1. 华中科技大学同济医学院附属荆州医院血液科(湖北荆州, 434020);
- 2. 湖北民族学院附属民大医院血液科;
- 3. 华中科技大学同济医学院附属协和医院;
- 4. 武汉市中心医院血液科;
- 5. 宜昌市中心人民医院血液科;
- 6. 中国人民解放军武汉总医院血液科;
- 7. 荆州市第一人民医院血液科;
- 8. 武汉市第四医院血液科;
- 9. 湖北医药学院附属襄阳市第一人民医院血液科;
- 10. 黄石市中心医院血液科;
- 11. 恩施土家族苗族自治州中心医院血液科;
- 12. 华中科技大学同济医学院附属同济医院血液科

详细信息

通讯作者: 向航,E-mail:3431620632@qq.com; 孟力,E-mail:mengli@tjh.tjmu.edu.cn

中图分类号: R733.72

收稿日期: 2017-01-19

Comparison of clinical efficacy and safety of frontline imatinib mesylate （Gleevec） and domestic imatinib mesylate （Gnico） in the treatment of newly diagnosed chronic myeloid leukemia in chronic phase

- 1. Department of Hematology, Jingzhou Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingzhou, 434020, China;
- 2. Department of Hematology, MinDa Hospital Affiliated to Hubei Institute for Nationalities;
- 3. Department of Hematology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology;
- 4. Department of Hematology, Wuhan Central Hospital;
- 5. Department of Hematology, Yichang Central People's Hospital;
- 6. Department of Hematology, Wuhan General Hospital of the Chinese People's Liberation Army;
- 7. Department of Hematology, the First People's Hospital of Jingzhou;
- 8. Department of Hematology, the Fourth Hospital of Wuhan;
- 9. Department of Hematology, Xiangyang No.;
- 1 People's Hospital, Hubei University of Medicine;
- 10. Department of Hematology, Huangshi Central Hospital;
- 11. Department of Hematology, the Central Hospital of Enshi Autonomous Prefecture;

More Information

Corresponding authors: XIANG Hang ; MENG Li

Received Date: 19 January 2017

摘要

摘要: 目的:对比分析国产伊马替尼(商品名:格尼可)和原研伊马替尼(格列卫)用于治疗慢性髓性白血病慢性期(CML-CP)患者的临床疗效与用药安全性差异。方法:回顾性分析42例接受格尼可治疗和83例接受格列卫治疗的CML-CP患者的临床资料,比较分析2组患者在3个月、6个月及12个月获得最佳疗效发生率的差异,对比2组患者发生血液学及非血液学不良反应发生率的差异。结果:2组患者3个月、6个月及12个月的最佳疗效发生率无统计学差异,不良反应发生率无统计学差异。结论:根据本次收集的临床资料分析结果,格尼可和格列卫治疗CML-CP患者的临床疗效相仿,患者对用药期间出现的不良反应均有良好的耐受性,显示出良好的用药安全性。
- 国产伊马替尼 /
- 原研伊马替尼 /
- 白血病,髓性,慢性 /
- 慢性期 /
- 疗效 /
- 安全性
Abstract: Objective:To compare and analyze the clinical efficacy and safety of imatinib mesylate (Gleevec) and domestic imatinib mesylate (Gnico) in the treatment of chronic myelogenous leukemia in chronic phase (CML-CP).Method:Forty-two patients with CML-CP were treated with Gnico and other 83 cases with Gleevec.The rates of optimal response in the 3rd,6th and 12th month were retrospectively compared between the two groups.We also analyzed the occurrence rate of hematologic and non-hematologic toxicities.Result:There was no significant difference in the rate of optimal response in the 3rd,6th and 12th month between the two groups.The incidence of adverse effect was not statistically significant.Conclusion:According to the results of this clinical data,Gleevec and Gnico have the similar clinical efficacy and safety for CML-CP patients.
- Gnico /
- Gleevec /
- chronic myeloid leukemia /
- chronic phase /
- efficacy /
- safety

HTML全文

参考文献(11)

[1]	Hughes TP,Hochhaus A,Branford S,et al.Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia:an analysis from the International Randomized Study of Interferon and STI571(IRIS)[J].Blood,2010,116:3758-3765.
[2]	Milojkovic D,Apperley J.Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia[J].Clin Cancer Res,2009,15:7519-7527.
[3]	陈娟,周励,杜圣红,等.国产伊马替尼治疗初发慢性髓性白血病的疗效与安全性观察[J].中华血液学杂志,2015,36(3):235-237.
[4]	Baccarani M,Deininger MW,Rosti G,et al.European LeukemiaNet recommendations for the management of chronic myeloid leukemia:2013[J].Blood,2013,22:872-884.
[5]	Sasaki K,Strom SS,O'Brien S,et al.Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era:analysis of patient data from six prospective clinical trials[J].Lancet Haematol,2015,2:e186-e193.
[6]	Kalmanti L,Saussele S,Lauseker M,et al.Safety and efficacy of imatinib in CML over a period of 10 years:data from the randomized CML-study IV[J].Leukemia,2015,29:1123-1132.
[7]	高冠论,许娜,周璇,等.甲磺酸伊马替尼和异基因造血干细胞移植治疗慢性髓细胞白血病慢性期的疗效分析[J].中华医学杂志,2013,93(38):3035-3039.
[8]	Hughes TP,Saglio G,Kantarjian HM,et al.Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib[J].Blood,2014,123:1353-1360.
[9]	江倩,赵东陆,金洁,等.国产甲磺酸伊马替尼治疗慢性髓性白血病慢性期早期疗效和安全性的前瞻性、多中心临床研究[J].中华血液学杂志,2015,36(8):651-655.
[10]	Saglio G,Kim DW,Issaragrisil S,et al.Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia[J].N Engl J Med,2010,362:2251-2259.
[11]	Wang J,Shen ZX,Saglio G,et al.Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase:ENESTchina[J].Blood,2015,125:2771-2778.